AbbVie Inc. $ABBV Shares Purchased by Public Sector Pension Investment Board

Public Sector Pension Investment Board boosted its position in shares of AbbVie Inc. (NYSE:ABBV) by 17.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,044,690 shares of the company’s stock after purchasing an additional 151,644 shares during the quarter. AbbVie makes up 0.9% of Public Sector Pension Investment Board’s portfolio, making the stock its 15th biggest holding. Public Sector Pension Investment Board owned 0.06% of AbbVie worth $241,888,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Evolution Wealth Management Inc. acquired a new stake in AbbVie in the 2nd quarter valued at about $26,000. Spurstone Advisory Services LLC acquired a new stake in shares of AbbVie in the second quarter valued at approximately $28,000. Financial Gravity Companies Inc. acquired a new stake in shares of AbbVie in the second quarter valued at approximately $36,000. Delos Wealth Advisors LLC purchased a new position in shares of AbbVie during the 2nd quarter worth approximately $39,000. Finally, Access Investment Management LLC acquired a new position in shares of AbbVie during the 2nd quarter worth approximately $44,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Record sales and upbeat execution: AbbVie reported record net sales and raised forward visibility after Q4 results, with analysts (e.g., Cantor Fitzgerald) reiterating bullish views and a $250 target tied to Skyrizi and Rinvoq strength. AbbVie Inc. (ABBV) Achieves Record Net Sales on Diversified Growth Platform
• Positive Sentiment: Korean post‑marketing Rinvoq study completed — bolsters real‑world evidence for Rinvoq in immunology, supporting long‑term revenue growth for the immunology franchise. Real‑world data can aid uptake and payer discussions. AbbVie’s Korean Rinvoq Study Wraps Up, Bolstering Real-World Data for Immunology Growth
• Neutral Sentiment: Analyst notes and reports are reframing valuation: recent analyst reports (Argus, other coverage) review AbbVie’s pipeline and valuation after strong results — useful for context but not a consensus catalyst. Analyst Report: AbbVie Inc
• Neutral Sentiment: Pipeline updates (elezanumab phase 2): AbbVie updated a Phase 2 study in acute cervical spinal cord injury — monitor readouts for potential long‑term upside but no immediate revenue impact. AbbVie Updates Phase 2 Elezanumab Study in Acute Cervical Spinal Cord Injury
• Neutral Sentiment: Small analyst PT trim from Evercore ISI: Evercore trimmed its price target modestly but kept an Outperform rating — suggests confidence in fundamentals despite nearer‑term headwinds. Evercore ISI Cuts AbbVie Inc. (ABBV) PT
• Negative Sentiment: Legal and policy risk: AbbVie sued HHS/CMS after Botox was selected for Medicare drug price negotiation under the Inflation Reduction Act — outcome could materially affect Botox pricing and margins. This litigation creates near‑term uncertainty. AbbVie sues US health agency over Botox price controls
• Negative Sentiment: Competitive pressure in immunology: J&J’s heavy Tremfya ad spend is intensifying competition for AbbVie’s Rinvoq and Skyrizi, which could pressure market share and growth trajectories in key indications. J&J’s Tremfya roars 2026 ad spend trailed by AbbVie’s Rinvoq and Skyrizi
• Negative Sentiment: U.S. operational changes and Medicaid concessions: AbbVie is reshaping U.S. operations and making Medicaid concessions to manage pricing headwinds — could weigh on near‑term U.S. margins even as it targets long‑term growth. AbbVie Reshapes U.S. Operations With Medicaid Concessions And Growth Focus

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Evercore lowered their target price on AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a report on Wednesday, February 4th. Citigroup reduced their price objective on AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 27th. Scotiabank started coverage on AbbVie in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price objective for the company. DZ Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price on the stock. in a report on Tuesday, November 4th. Finally, HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and raised their price target for the stock from $225.00 to $265.00 in a research note on Wednesday, December 10th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $251.00.

AbbVie Trading Up 3.0%

NYSE ABBV opened at $227.57 on Friday. The company has a market capitalization of $402.20 billion, a PE ratio of 96.43, a price-to-earnings-growth ratio of 0.77 and a beta of 0.35. The business’s 50-day moving average price is $223.45 and its 200 day moving average price is $220.35. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The company’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.